Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-κB and cell growth in U87MG human malignant glioma cells.

“Nuclear factor (NF)-κB is the key transcription factor involved in the inflammatory responses, and its activation aggravates tumors. Peptidoglycan (PGN), a main cell wall component of Gram-positive bacteria, stimulates Toll-like receptor 2 (TLR-2) and activates a number of inflammatory pathways, including NF-κB…

Cannabinoids have been reported to exert anti-inflammatory and antitumor effects…

Our finding that cannabinoids suppress the NF-κB inflammatory pathway and cell growth via CB1 receptors in glioma cells provides evidence for the therapeutic potential of targeting cannabinoid receptors for the treatment of inflammation-dependent tumor progression.”

http://www.ncbi.nlm.nih.gov/pubmed/22842590

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Medical marijuana as protection against the H1N1 swine flu virus?

“When the immune system attacks a flu virus, it causes widespread inflammation throughout the body. This inflammation presents itself in runny noses, soar throats, and body aches that accompany influenza. Runaway inflammation can cause the immune system to destroy the body it was meant to protect and lead to death.

 ”When inflammation goes off the handle, the body releases endocannabinoids, which are natural chemicals that suppress the immune system, taking down the inflammation before it does more harm than good. This endocannabinoid system, as it’s called, is one of the many systems responsible for maintaining balance and health in the body,” ABC News reported.

If the endocannabinoid system cannot keep up – which often happens in very severe influenza infections – organ failure, particularly lung failure, may result.

 ”They die not from the virus itself but from their own immune response,” Melamede told ABC News.
Cannabis Science intends to solve this threat. Marijuana contains natural, plant-based cannabinoids, called phytocannabinoids. A medical marijuana lozenge provides the body with a boost of endocannabinoids and helps to relieve the dangerous inflammation.
While viruses like the H1N1 swine flu bug are clever in their ability to mutate and outsmart even the latest vaccines, the human body’s response – with regard to inflammation management – does not change. Cannabis Science may be on to something here.”

http://digitaljournal.com/article/276928

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Obesity and cannabis use: results from 2 representative national surveys.

“We hypothesized that the prevalence of obesity would be higher in cannabis users than in nonusers… this analysis showed that even if cannabis consumption increases appetite, people using cannabis are less likely to be obese than people who do not use cannabis…

The authors conclude that the prevalence of obesity is lower in cannabis users than in nonusers.”

http://www.ncbi.nlm.nih.gov/pubmed/21868374
http://aje.oxfordjournals.org/content/174/8/929.long

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Medical Marijuana Laws and Suicides by Gender and Age.

“We estimated the association between legalizing medical marijuana and suicides…

Conclusions. Suicides among men aged 20 through 39 years fell after medical marijuana legalization compared with those in states that did not legalize.

The negative relationship between legalization and suicides among young men is consistent with the hypothesis that marijuana can be used to cope with stressful life events.”

 http://www.ncbi.nlm.nih.gov/pubmed/24432945

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience.

“In this article, real-life data from clinical practice showing specific aspects relating to use of 9-delta-tetrahydocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex®) in patients with moderate to severe spasticity resistant to usual therapy will be presented…

These case reports highlight the diverse nature of the MS spasticity population and they show the possible usefulness of THC:CBD oromucosal spray in individual patients with moderate to severe spasticity resistant to existing therapies…

Perhaps the most important finding is the possibility of obtaining relevant improvements in QoL/ADL (quality of life/activities of daily living) in some patients with resistant MS spasticity, allowing them to engage back in physical and social activities.”

http://www.ncbi.nlm.nih.gov/pubmed/24457847

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies.

“New clinical experience with 9-delta-tetrahydocannabinol (THC) and cannabidiol (CBD) oromucosal spray (Sativex®)…

A randomized, placebo controlled long-term follow-up clinical trial with THC:CBD spray versus placebo demonstrated that it was not associated with cognitive decline, depression or significant mood changes…

THC:CBD oromucosal spray did not adversely influence standard driving ability in patients with moderate to severe MS spasticity…

Findings to date reinforce the efficacy and safety observed in Phase III clinical trials…

Importantly, no additional safety concerns were identified…

Thus, these new data support a positive benefit-risk relationship for THC:CBD oromucosal spray during longer-term use.”

http://www.ncbi.nlm.nih.gov/pubmed/24457846

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Cannabinoid type-1 receptor ligands, alone or in combination with cocaine, affect vigilance-related behaviors of marmoset monkeys.

“Endocannabinoids (eCB) have been functionally linked to cocaine’s rewarding effects.

…changes in CB1r function – alone and in combination with cocaine – affected stereotyped vigilance-related behaviors… further implicating the eCB system in the neurobiological mechanisms of cocaine addiction.”

http://www.ncbi.nlm.nih.gov/pubmed/24445195

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Repositioning therapy for thyroid cancer: new insights on established medications.

“Experimental in vitro and in vivo evidence, as well as results of clinical studies, have indicated that molecular targets for medications currently available for the treatment of mood disorders, sexually transmitted diseases, metabolic disorders, and diabetes may be active and relevant in thyroid cancer.

For instance, the derivatives of cannabis and an anti-diabetic agent, metformin, are both able to inhibit extracellular signal-regulated protein kinase (ERK), which is commonly activated in thyroid cancer cells.

We present here several examples of well-known medications that have the potential to become new therapeutics for patients with thyroid cancer. Repositioning of established medications for the treatment of thyroid cancer could broaden the scope of current therapeutic strategies. These diverse treatment choices could allow physicians to provide an individualized approach to optimize treatment for patients with thyroid cancer.”

http://www.ncbi.nlm.nih.gov/pubmed/24446492

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

The isolation and identification of two compounds with predominant radical scavenging activity in hempseed (seed of Cannabis sativa L.).

“Forty samples were extracted from defatted kernels and hulls of two varieties of hempseed (Bama and Yunma No. 1)…

Two compounds, with predominant antiradical activity, were isolated…

N-trans-caffeoyltyramine and cannabisin B….

The two compounds exhibited significant high DPPH() scavenging activity and protective effect against in vitro oxidation of human low-density lipoprotein compared with extracts from flaxseed, grape seed, and soybean.

This suggests that hempseed hull extract is a potential source of natural antioxidants, which could be added to dietary supplements to help prevent oxidative stress.”

http://www.ncbi.nlm.nih.gov/pubmed/23107724

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Beyond radio-displacement techniques for Identification of CB1 Ligands: The First Application of a Fluorescence-quenching Assay.

“Cannabinoid type 1 Receptor (CB1) belongs to the GPCR family and it has been targeted, so far, for the discovery of drugs aimed at the treatment of neuropathic pain, nausea, vomit, and food intake disorders. Here, we present the development of the first fluorescent assay enabling the measurement of kinetic binding constants for CB1orthosteric ligands…

…a sustainable valid alternative to the expensive and environmental impacting radiodisplacement techniques and paves the way for an easy, fast and cheap high-throughput drug screening toward CB1 for identification of new orthosteric and allosteric modulators.”

http://www.ncbi.nlm.nih.gov/pubmed/24441508

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous